Get the Stockscreener App
5.12
1.73%
-0.09
After Hours:
5.00
-0.12
-2.34%
Puma Biotechnology Inc stock is traded at $5.12, with a volume of 428.10K.
It is down -1.73% in the last 24 hours and up +12.78% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$5.21
Open:
$5.24
24h Volume:
428.10K
Relative Volume:
0.72
Market Cap:
$257.90M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
8.3934
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
-0.19%
1M Performance:
+12.78%
6M Performance:
+86.86%
1Y Performance:
+88.93%
1-Day Range:
$5.11
$5.415
1-Week Range:
$4.88
$5.415
52-Week Range:
$2.32
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.12 | 262.43M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Real time social sentiment graph for Puma Biotechnology Inc.Trade Volume Report & AI Powered Buy/Sell Recommendations - newser.com
Puma Biotechnology (NASDAQ:PBYI) Raised to Buy (B-) at Weiss Ratings - MarketBeat
What’s next for Puma Biotechnology Inc. stock price2025 Winners & Losers & Verified Swing Trading Watchlists - newser.com
Leading vs lagging indicators on Puma Biotechnology Inc. performanceLong Setup & Accurate Technical Buy Alerts - newser.com
Published on: 2025-10-10 03:15:11 - newser.com
Analyzing drawdowns of Puma Biotechnology Inc. with statistical toolsJuly 2025 Weekly Recap & Fast Momentum Entry Tips - newser.com
Will Puma Biotechnology Inc. stock benefit from sector rotationMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Momentum divergence signals in Puma Biotechnology Inc. chartJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Is Puma Biotechnology Inc. stock a safe investment in uncertain marketsSwing Trade & Daily Stock Momentum Reports - newser.com
Will Puma Biotechnology Inc. stock go up soonM&A Rumor & Safe Entry Point Identification - newser.com
Pattern recognition hints at Puma Biotechnology Inc. upsideCEO Change & Fast Momentum Entry Tips - newser.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635c4 - MarketScreener
Comparing Puma Biotechnology Inc. in custom built stock radarsJuly 2025 Retail & Daily Stock Trend Reports - newser.com
Live market analysis of Puma Biotechnology Inc.Trade Entry Summary & Fast Gain Stock Trading Tips - newser.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 - BioSpace
Puma Biotechnology reports inducement awards under Nasdaq listing rule - MarketScreener
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT - MSN
What Do Analysts Think About Puma Biotechnology (PBYI)? - MSN
What analysts say about Puma Biotechnology Inc stockEarnings Per Share Trends & Low Entry Investment Ideas - earlytimes.in
Using data tools to time your Puma Biotechnology Inc. exitEarnings Overview Summary & Accurate Intraday Trading Signals - newser.com
September 2025's Promising Penny Stocks Revealed - simplywall.st
Puma Biotechnology Inc Stock Analysis and ForecastLow Risk Investment Ideas & Free Stay Informed With Forecasts - earlytimes.in
Tools to monitor Puma Biotechnology Inc. recovery probabilityJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Is Puma Biotechnology Inc a good long term investmentExit Strategy Tips & Explosive Capital Gains - Early Times
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):